Dupixent® (dupilumab)

BL 761055

Dupixent® (dupilumab)

BL 761055

U.S. License Holder:

Regeneron Pharmaceuticals

Date of License:

March-28-2017

Last Update:

Nov-30-2023

approved_indications FDA-Approved Indications

DUPIXENT (dupilumab) is an interleukin-4 receptor alpha antagonist indicated:

Atopic Dermatitis: For the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids;

Asthma: As an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma;

Chronic Rhinosinusitis with Nasal Polyposis: As an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP);

Eosinophilic Esophagitis: For the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE);

Prurigo Nodularis: For the treatment of adult patients with prurigo nodularis (PN).

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2017-01129

U.S. Patent No.
8,679,487 (Anti-interleukin-4 receptor antibodies)

Patent Owner
Immunex Corp.

Petitioner(s)
Genzyme Corp.; Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis US LLC

§ 102 Challenge
Y: Claims 1-17

Claim Types Challenged Under § 102
Composition of Matter Formulation (Pharmaceutical Composition) Other (Kit)

§ 102 Challenge Instituted
N

§ 103 challenge
N

IPR Status
IPR Not Instituted

IPR2017-01879

U.S. Patent No.
8,679,487 (Anti-interleukin-4 receptor antibodies)

Patent Owner
Immunex Corp.

Petitioner(s)
Aventisub LLC; Genzyme Corp.; Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC

§ 102 Challenge
Y: Claims 1-14, 16, 17

Claim Types Challenged Under § 102
Composition of Matter Formulation (Pharmaceutical Composition) Other (Kit)

§ 102 Challenge Instituted
Y

§ 103 challenge
N

Federal Circuit Appeal(s)
19-1777 (condolidated with lead appeal 17-1749)

Supreme Court Appeal(s)
20-1285

IPR Status
Final Written Decision (No Instituted Claims Found Unpatentable); Federal Circuit Appeal Dismissed; Writ of Certiorari Denied

IPR2017-01884

U.S. Patent No.
8,679,487 (Anti-interleukin-4 receptor antibodies)

Patent Owner
Immunex Corp.

Petitioner(s)
Aventisub LLC; Genzyme Corp.; Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-17

Claim Types Challenged Under § 103
Composition of Matter Formulation (Pharmaceutical Composition) Other (Kit)

§ 103 Challenge Instituted
Y

Federal Circuit Appeal(s)
19-1749 (lead appeal, consolidated with 19-1777)

Supreme Court Appeal(s)
20-1285

IPR Status
Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Affirmed; Writ of Certiorari Denied

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:17-cv-10465 (D. Mass.)

U.S. Patent Nos.
8,679,487 (Anti-Interleukin-4 Receptor Antibodies)

Plaintiffs
Sanofi-Aventis U.S. LLC; Genzyme Corp.; Regeneron Pharmaceuticals, Inc.

Defendants
Amgen Inc.; Immunex Corp.

Status
Dismissed

BPCIA
N

2:17-cv-02613 (C.D. Cal.)

U.S. Patent Nos.
8,679,487 (Anti-Interleukin-4 Receptor Antibodies)

Plaintiffs
Sanofi; Sanofi-Aventis U.S. LLC; Genzyme Corp.; Aventisub LLC; Regeneron Pharmaceuticals, Inc.

Defendants
Immunex Corp.; Amgen Inc. (Interested party)

Status
Case Ongoing

BPCIA
N

Related News

Venable’s BiologicsHQ Monthly Injection – June 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 13, 2021
Venable’s BiologicsHQ Monthly Injection – March 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
April 7, 2021
Venable’s BiologicsHQ Monthly Injection – October 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
November 9, 2020
Venable’s BiologicsHQ Monthly Injection – April 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
May 7, 2019
Venable’s BiologicsHQ Monthly Injection – February 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
March 6, 2019
Venable’s BiologicsHQ Monthly Injection – February 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
March 6, 2018
Venable’s BiologicsHQ Monthly Injection – August/September 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
October 5, 2017

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha